European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-30

Epigenetics and microRNAs in Myocardial Function and Disease

Objetivo

Heart failure (HF) is the ultimate outcome of many cardiovascular diseases. Re-expression of fetal genes in the adult heart contributes to development of HF. Two mechanisms involved in the control of gene expression are epigenetics and microRNAs (miRs). We propose a project on epigenetic and miR-mediated mechanisms leading to HF.
Epigenetics refers to heritable modification of DNA and histones that does not modify the genetic code. Depending on the type of modification and on the site affected, these chemical changes up- or down-regulate transcription of specific genes. Despite it being a major player in gene regulation, epigenetics has been only partly investigated in HF. miRs are regulatory RNAs that target mRNAs for inhibition. Dysregulation of the cardiac miR signature occurs in HF. miR expression may itself be under epigenetic control, constituting a miR-epigenetic regulatory network. To our knowledge, this possibility has not been studied yet.
Our specific hypothesis is that the profile of DNA/histone methylation and the cross-talk between epigenetic enzymes and miRs have fundamental roles in defining the characteristics of cells during cardiac development and that the dysregulation of these processes determines the deleterious nature of the stressed heart’s gene programme. We will test this first through a genome-wide study of DNA/histone methylation to generate maps of the main methylation modifications occurring in the genome of cardiac cells treated with a pro-hypertrophy regulator and of a HF model. We will then investigate the role of epigenetic enzymes deemed important in HF, through the generation and study of knockout mice models. Finally, we will test the possible therapeutic potential of modulating epigenetic genes.
We hope to further understand the pathological mechanisms leading to HF and to generate data instrumental to the development of diagnostic and therapeutic strategies for this disease.

Convocatoria de propuestas

ERC-2011-ADG_20110310
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-AG - ERC Advanced Grant

Institución de acogida

HUMANITAS MIRASOLE SPA
Aportación de la UE
€ 2 500 000,00
Dirección
VIA MANZONI 56
20100 Rozzano (Mi)
Italia

Ver en el mapa

Región
Nord-Ovest Lombardia Milano
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Investigador principal
Gianluigi Condorelli (Prof.)
Contacto administrativo
Danilo Petroni (Mr.)
Enlaces
Coste total
Sin datos

Beneficiarios (1)